Single-cell multi-omics technologies and methods characterize cell states and activities by
simultaneously integrating various single-modality omics methods that profile the …

The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …

Around 40–50% of all triple-negative breast cancer (TNBC) patients achieve a pathological
complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). The …

Immune evasion is a hallmark of cancer, enabling tumors to survive contact with the host
immune system and evade the cycle of immune recognition and destruction. Here, we …

The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …

In triple-negative breast cancer (TNBC), stromal restriction of CD8+ T cells associates with
poor clinical outcomes and lack of responsiveness to immune-checkpoint blockade (ICB). To …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Tumor immunosuppressive microenvironment (TIME) often causes suppression of anti-
tumor immunity and increases susceptibility to tumor recurrence and metastasis. Herein, a …

Simple Summary Although immune check point inhibitors have been established as a new
paradigm in cancer treatment, they have shown no clinical benefit in immune excluded or …